$1.16 Billion is the total value of Redmile Group, LLC's 50 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
XNCR | New | XENCOR INC | $26,217,000 | – | 996,100 | +100.0% | 2.26% | – |
ESRX | New | EXPRESS SCRIPTS HLDG CO | $23,306,000 | – | 338,800 | +100.0% | 2.01% | – |
PTHN | New | PATHEON N V | $12,653,000 | – | 440,720 | +100.0% | 1.09% | – |
ANTM | New | ANTHEM INC | $11,102,000 | – | 77,223 | +100.0% | 0.96% | – |
EHTH | New | EHEALTH INC | $10,625,000 | – | 997,621 | +100.0% | 0.92% | – |
IRTC | New | IRHYTHM TECHNOLOGIES INC | $6,864,000 | – | 228,800 | +100.0% | 0.59% | – |
GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $4,572,000 | – | 316,400 | +100.0% | 0.39% | – |
DVAX | New | DYNAVAX TECHNOLOGIES CORP | $4,147,000 | – | 1,049,791 | +100.0% | 0.36% | – |
RARX | New | RA PHARMACEUTICALS INC | $2,739,000 | – | 180,310 | +100.0% | 0.24% | – |
ACRS | New | ACLARIS THERAPEUTICS INC | $2,557,000 | – | 94,200 | +100.0% | 0.22% | – |
DPLO | New | DIPLOMAT PHARMACY INC | $1,932,000 | – | 153,317 | +100.0% | 0.17% | – |
IBB | New | ISHARES TRnasdq biotec etf | $1,194,000 | – | 4,500 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
INVITAE CORP | 32 | Q3 2023 | 2.7% |
REGENXBIO INC | 28 | Q3 2023 | 3.8% |
CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
4 | 2024-05-10 |
4 | 2024-04-01 |
4 | 2024-04-01 |
4 | 2024-03-25 |
SC 13D/A | 2024-03-25 |
4 | 2024-03-19 |
4 | 2024-03-14 |
4 | 2024-03-13 |
SC 13D/A | 2024-03-13 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.